Respivert’s multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449

Bibliography

• Lee JC, Young PR. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol 1996;59(2):152-7
   PubMed Web of Science ®Google Scholar
• Salituro FG, Germann UA, Wilson KP, et al. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem 1999;6(9):807-23
   PubMed Web of Science ®Google Scholar
• Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;185-201
   Google Scholar
• Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372(6508):739-46
   PubMed Web of Science ®Google Scholar
• Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005;8(4):421-30
   PubMedGoogle Scholar
• Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139(6):1470-9
   PubMed Web of Science ®Google Scholar
• Watz H, Barnacle H, Hartley BF, Chan R. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014;2(1):63-72
   PubMed Web of Science ®Google Scholar
• MacNee W, Allan RJ, Jones I, et al. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013;68(8):738-45
   PubMed Web of Science ®Google Scholar
• Millan DS. What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease? Future Med Chem 2011;3(13):1635-45
   PubMed Web of Science ®Google Scholar
• Millan DS, Bunnage ME, Burrows JL, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem 2011;54(22):7797-814
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson, Centocor Ortho Biotech Inc. Acquires RespiVert Ltd.,Strengthens pulmonary focus acquisition bolsters pulmonary portfolio and capabilities, accessing promising pipeline of first-in-class compounds and renowned team of respiratory scientists. Press release, 1 June 2010
   Google Scholar
• Charron C, Coates M, Ito K, et al. Superior effects of rv568, a novel narrow spectrum kinase inhibitor, to BIRB796, a p38MAPK inhibitor, on pro-inflammatory cytokine roduction [abstracts A3088]. In macrophages, ajrccm-conference.2011.183.1_Meeting, American Thoracic Society 2011 International Conference; 13-18 May 2011, Denver Colorado
   Google Scholar
• Kizawa Y, Kimura G, Saito R, et al. Effects Of RV568, a narrow spectrum kinase inhibitor, on airway inflammation and hyperresponsiveness [abstracts A3103]. In tobacco-smoke exposed mice, ajrccm-conference.2011.183.1_Meeting, American Thoracic Society 2011 International Conference; 13-18 May 2011, Denver Colorado
   Google Scholar
• Langenbach S, Dousha L, Gualano RC, et al. Anti-viral effects of RV568, a Narrow Spectrum Kinase Inhibitor (NSKI) [abstracts A3362]. In Respiratory Syncytial Virus (RSV) infected mice, ajrccm-conference.2011.183.1_Meeting, American Thoracic Society 2011 International Conference; 13-18 May 2011, Denver Colorado
   Google Scholar
• Onions S. The discovery and profile of narrow spectrum kinase inhibitors as novel treatments for inflammatory pulmonary disease. 17th RSC/SCI Medicinal Chemistry Symposium; September 2013; Cambridge
   Google Scholar
• Respivert Limited. p38 map kinase inhibitors. WO2010038085; 2010
   Google Scholar
• Respivert Limited. p38 map kinase inhibitors. WO2010038086; 2010
   Google Scholar
• Respivert Limited. p38 map kinase inhibitors. WO/2010/067130; 2010
   Google Scholar
• Respivert Limited. p38 map kinase inhibitors. WO/2010/067131; 2010
   Google Scholar
• Respivert Limited. p38 map kinase inhibitor. WO/2010/112936; 2010
   Google Scholar
• Respivert Limited. Ureido-Pyrazole derivatives for use in the treatment of respiratory syncitial virus (rsv) infection. WO2011158039; 2011
   Google Scholar
• Respivert Limited. Ureido-Pyrazole derivatives for use in the treatment of rhinovirus infections. WO2011158042; 2011
   Google Scholar
• Respivert Limited. Inhibitors of hemopoietic cell kinase (p59-Hck) and their use in the treatment of influenza infection. WO2011070369; 2011
   Google Scholar
• Respivert Limited. Respiratory formulations containing P38 mapk inhibitors. WO2011158044; 2011
   Google Scholar
• Respivert Limited. p38 Map Kinase Inhibitors. WO2011124930; 2011
   Google Scholar
• Respivert Limited. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. WO2013050756; 2013
   Google Scholar
• Respivert Limited. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. WO2013050757; 2013
   Google Scholar
• Respivert Limited. Pyrazolyl ureas as kinase inhibitors. WO2014027209; 2014
   Google Scholar
• Respivert Limited, Topivert Pharma Limited. Kinase inhibitors. WO-2014033446; 2014
   Google Scholar
• Respivert Limited, Topivert Pharma Limited. Kinase inhibitors. WO-2014033447; 2014
   Google Scholar
• Respivert Limited, Topivert Pharma Limited. Pyrazole derivatives as p38 map inhibitors. WO-2014033448; 2014
   Google Scholar
• Respivert Limited, Topivert Pharma Limited. Kinase inhibitors. WO-2014033449; 2014
   Google Scholar
• Pulmagen Therapeutics (Inflammation) Limited. Triazolopyridine derivatives as p38 map kinase inhibitors. WO 2010094956; 2010
   Google Scholar
• Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 2008;27(56):7055-69
   Google Scholar
• Tintori C, Laurenzana I, La Rocca F, et al. Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents. ChemMedChem 2013;8(8):1353-60
   Google Scholar
• Saito Y, Yuki H, Kuratani M, et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med 2013;5(181):181ra52
   PubMedGoogle Scholar
• Matsubara S, Li G, Takeda K, et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006;173(1):56-63
   PubMed Web of Science ®Google Scholar
• Norman P. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013. Expert Opin Ther Pat 2014;24(5):573-95
   PubMed Web of Science ®Google Scholar